Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Strontium Chloride, Sr-89
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Brand Name : Metastron
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Strontium Chloride, Sr-89
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?